66 related articles for article (PubMed ID: 1687728)
1. Marker rhythmometry with macrophage-colony stimulating factor (M-CSF).
Elg S; Halberg E; Ramakrishnan S; Cornélissen G; Haus E; Nicolau G; Carson L; Twiggs L; Long HJ; Halberg F
Chronobiologia; 1991; 18(4):141-52. PubMed ID: 1687728
[TBL] [Abstract][Full Text] [Related]
2. Macrophage colony-stimulating factor as a marker for malignant germ cell tumors of the ovary.
Suzuki M; Kobayashi H; Ohwada M; Terao T; Sato I
Gynecol Oncol; 1998 Jan; 68(1):35-7. PubMed ID: 9454657
[TBL] [Abstract][Full Text] [Related]
3. Macrophage colony-stimulating factor as a tumor marker for epithelial ovarian cancer.
Suzuki M; Ohwada M; Aida I; Tamada T; Hanamura T; Nagatomo M
Obstet Gynecol; 1993 Dec; 82(6):946-50. PubMed ID: 8233270
[TBL] [Abstract][Full Text] [Related]
4. Toward salivary-urinary chronosensitivity testing: chronomes of OVX1, M-CSF and CA130.
Xu F; Yu Y; Bast RC; Cornélissen G; Fujii S; Takagi M; O'Brien T; Halberg F
In Vivo; 1995; 9(4):407-12. PubMed ID: 8555442
[TBL] [Abstract][Full Text] [Related]
5. Serum macrophage colony-stimulating factor (M-CSF) levels in patients with epithelial ovarian cancer.
Gadducci A; Ferdeghini M; Castellani C; Annicchiarico C; Prontera C; Facchini V; Bianchi R; Genazzani AR
Gynecol Oncol; 1998 Jul; 70(1):111-4. PubMed ID: 9698485
[TBL] [Abstract][Full Text] [Related]
6. [The plasma levels and diagnostic utility of granulocyte colony stimulating factor (G-CSF) and macrophage - colony stimulating factor (M-CSF) in ovarian cancer patients].
ławicki S; Czygier M; Gacuta-Szumarska E; Knapp P; Szmitkowski M
Pol Merkur Lekarski; 2006 Nov; 21(125):465-8. PubMed ID: 17345841
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of combined use of macrophage colony-stimulating factor and squamous cell carcinoma antigen as a selective diagnostic marker for squamous cell carcinoma arising in mature cystic teratoma of the ovary.
Suzuki M; Tamura N; Kobayashi H; Ohwada M; Terao T; Sato I
Gynecol Oncol; 2000 Jun; 77(3):405-9. PubMed ID: 10831350
[TBL] [Abstract][Full Text] [Related]
8. Chronobiologic aspects of urinary gonadotropin peptide (UGP).
Cornélissen G; Halberg F; Walker R; Zaslavskaya RM; Fine RL; Haus E
In Vivo; 1995; 9(4):359-62. PubMed ID: 8555435
[TBL] [Abstract][Full Text] [Related]
9. [Macrophage-colony stimulating factor and ovarian cancer].
Menditto A; Piscittelli V; Cassese F; Balbi GC; Balbi C; Cardone A
Minerva Ginecol; 1999; 51(7-8):261-4. PubMed ID: 10536419
[TBL] [Abstract][Full Text] [Related]
10. Urinary gonadotropin peptide (UGP) as a marker of gynecologic malignancies.
Walker R; Crebbin V; Stern J; Scudder S; Schwartz P
Anticancer Res; 1994; 14(5A):1703-9. PubMed ID: 7847804
[TBL] [Abstract][Full Text] [Related]
11. Serum macrophage-colony stimulating factor levels in colorectal cancer patients correlate with lymph node metastasis and poor prognosis.
Mroczko B; Groblewska M; Wereszczyńska-Siemiatkowska U; Okulczyk B; Kedra B; Łaszewicz W; Dabrowski A; Szmitkowski M
Clin Chim Acta; 2007 May; 380(1-2):208-12. PubMed ID: 17368603
[TBL] [Abstract][Full Text] [Related]
12. Significant correlation of matrix metalloproteinase and macrophage colony-stimulating factor serum concentrations in patients with head and neck cancer.
Kuropkat C; Duenne AA; Herz U; Renz H; Werner JA
Neoplasma; 2004; 51(5):375-8. PubMed ID: 15640942
[TBL] [Abstract][Full Text] [Related]
13. Toward a chronotherapy of ovarian cancer with taxol. Part I: Basic background.
Cornélissen G; Halberg E; Long HJ; Prem K; Bakken E; Touitou Y; Elg S; Haus E; Halberg F
Chronobiologia; 1991; 18(4):153-66. PubMed ID: 1687729
[No Abstract] [Full Text] [Related]
14. Salvage weekly paclitaxel in recurrent ovarian cancer.
Abu-Rustum NR; Aghajanian C; Barakat RR; Fennelly D; Shapiro F; Spriggs D
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-62-S15-67. PubMed ID: 9346225
[TBL] [Abstract][Full Text] [Related]
15. Tumor necrosis factor administration is associated with increased endogenous production of M-CSF and G-CSF but not GM-CSF in human cancer patients.
Logan TF; Gooding W; Kirkwood JM; Shadduck RK
Exp Hematol; 1996 Jan; 24(1):49-53. PubMed ID: 8536792
[TBL] [Abstract][Full Text] [Related]
16. Toward a chronotherapy of ovarian cancer with taxol. Part II: Test pilot study on circulating CA125.
Halberg E; Long HJ; Cornélissen G; Blank MA; Elg S; Touitou Y; Bakken E; Delmore P; Haus E; Sackett-Lundeen L
Chronobiologia; 1992; 19(1-2):17-42. PubMed ID: 1352750
[No Abstract] [Full Text] [Related]
17. Paclitaxel in the treatment of patients with upper gastrointestinal carcinomas.
Ajani JA; Ilson DH; Kelsen DP
Semin Oncol; 1996 Oct; 23(5 Suppl 12):55-8. PubMed ID: 8941411
[TBL] [Abstract][Full Text] [Related]
18. Urinary human chorionic gonadotropin free beta-subunit and beta-core fragment: a new marker of gynecological cancers.
Cole LA; Wang YX; Elliott M; Latif M; Chambers JT; Chambers SK; Schwartz PE
Cancer Res; 1988 Mar; 48(5):1356-60. PubMed ID: 3342414
[TBL] [Abstract][Full Text] [Related]
19. Phase I and pharmacological study of single paclitaxel administered weekly for heavily pre-treated patients with epithelial ovarian cancer.
Takano M; Kikuchi Y; Kita T; Suzuki M; Ohwada M; Yamamoto T; Yamamoto K; Inoue H; Shimizu K
Anticancer Res; 2002; 22(3):1833-8. PubMed ID: 12168878
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1.
Chambers SK; Kacinski BM; Ivins CM; Carcangiu ML
Clin Cancer Res; 1997 Jun; 3(6):999-1007. PubMed ID: 9815777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]